Clinical Trial Update: A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating a novel basal insulin titration approach (LY2963016) in type 2 diabetes was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LY2963016 (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | Phase 4 | Status: WITHDRAWN